Steve Elms, Director at Marker Therapeutics, Inc. (MRKR), bought 11,085 shares at $3.20 ($35K) on 2024-12-23, disclosed to the SEC on 2024-12-26.
Open-market purchase of $35k MRKR by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| ADMA | SELL | 2024-03-19 | $5.6M | — | Filing → |
| ADMA | SELL | 2024-03-15 | $10.2M | — | Filing → |
| MRKR | BUY | 2021-03-18 | $4.0M | — | Filing → |